Declan Jones, PhD joined Janssen Neuroscience as VP and Neuroscience Lead in June 2013 located at the J&J Innovation Centre in London. Declan previously worked for GSK’s Centre of Excellence for External Drug Discovery (CEEDD) as Head of Research. He was responsible for creating scientific strategies, identifying external opportunities, and managing programs from preclinical to Phase II programs across all therapeutic areas.
Prior to GSK’s CEEDD, he spent 14 years in GSK’s neuroscience R&D, finishing as Head of In Vivo Neurobiology and Strategy Leader for schizophrenia and bipolar disorders within the Psychiatry Centre of Excellence for Drug Discovery. His Department helped identify 12 clinical development candidates for psychiatry and neurology, and provided in vivo support for a number of marketed assets, including Seroxat, Lamictal, Wellbutrin and Requip. Declan was the recipient of an R&D Pipeline award for his leadership of a schizophrenia program with a successful Phase II outcome.
Declan received his PhD from the University of Bradford and did post-doctoral work at Emory University and Glaxo. He served as a core panel member for Neuroscience on the BBSRC grant committee for a 3 year term. He is currently an Executive Team member for the Dementias Platform UK (DPUK) and the Wellcome Trust Neuroinflammation Consortium, and is a SAB member for the UK Dept of Health (PM’s Dementia Challenge) and the South London and Maudsely NHS Foundation Trust Biomedical Research Centre at the Institute of Psychiatry, Psychology, and Neuroscience (King’s College London), and works closely with the Dementia Discovery Fund.